Table 1: Clinical Characteristics of 39 patients with type 2 diabetes.
Value are expressed as mean±SD, P value: statistical difference vs. Noninhibitor group, ACR Values are additionally expressed in median and extremes No statistical significance in values between DPP4 inhibitor group vs. Non-inhibitor group HOMA-IR: Homeostasis model assessment of insulin resistance, NGSP: revised by the National Glycohemoglobin Standardization Program, LDL-cholesterol: Low density lipoproteincholesterol, eGFR: Estimated glomerular filtration rate
| | Non inhibitor group | DPP4 inhibitor group | (p Value) |
| N | | 19 | 20 | |
| Age | [years] | 64±15 | 67±10 | |
| Sex | [male/total] | 14/19 | 14/20 | |
| Medication |
| Angiotensin II receptor blockers | [/total] | 19/19 | 20/20 | |
| Calcium channel blockers | [/total] | 12/19 | 12/20 | |
| Diuretics | [/total] | 6/19 | 6/20 | |
| Sulfonylureas | [/total] | 6/19 | 6/19 | |
| Biguanides | [/total] | 8/19 | 6/19 | |
| α-glucosidase inhibitor | [/total] | 9/19 | 10/20 | |
| stains | [/total] | 7/19 | 7/20 | |
| Systolic blood pressure | [mmHg] | 126±11 | 132±16 | (0.2659) |
| Diastolic blood pressure | [mmHg] | 79±9 | 79±7 | (0.6168) |
| Body mass Index | [Kg/m2] | 25.879±3.6 | 26±3.8 | (0.7369) |
| HOMI-IR | | 2.63±2.29 | 2.54±2.98 | (0.4133) |
| Hemoglobin A1c[NGSP] | [%] | 7.28±1.44 | 7.24±1.22 | (0.7924) |
| LDL-cholesterol | [mmol/L] | 2.79±0.7 | 3.15±0.78 | (0.3576) |
| Triglyceride | [mmol/L] | 1.22±0.69 | 1.63±0.82 | (0.1403) |
| eGFR | [mL/min] | 73.99±25.9 | 68.9±19.9 | (0.5593) |
| Albumin/creatinine ratio | [mg/ mmolCr] | 4.68±3.85 | 3.51±5.18 | |
| Median(interquartile range ) | | 2.36(0.97- 7.00) | 3.81(1.75- 6.78) | (0.1326) |